Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Decreases By 34.6%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 218,800 shares, a decrease of 34.6% from the May 31st total of 334,700 shares. Based on an average trading volume of 4,960,000 shares, the days-to-cover ratio is presently 0.0 days.

Biodexa Pharmaceuticals Trading Up 2.9 %

Shares of BDRX opened at $0.90 on Monday. The firm has a 50-day moving average of $1.06 and a 200-day moving average of $1.44. Biodexa Pharmaceuticals has a one year low of $0.67 and a one year high of $9.74. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.26 and a quick ratio of 1.26.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.